According to a quantitative analysis of data to compare LDH and S100 B's prognostic and discriminative ability for melanoma, six eligible studies, which included 1,033 patients with cutaneous melanoma, serum S100B showed significantly greater discriminative ability in identifying disease relapse [pooled area Under the ROC (AUROC) 78.64 (95% CI 70.28; 87.01)] compared to serum LDH [AUROC 64.41 (95% CI 56.05; 72.78)] (p=0.013). Here, S100B is linked to melanoma.